glp-1-based treatments approved for weight loss 2025 What are GLP-1s? GLP-1 Weight Loss Drugs: How

Healthcare professionals and patients are encouraged to report suspected adverse reactions via the Yellow Card Scheme (yellowcard.mhra.gov.uk), and the overall benefit-risk profile remains favourable for appropriate patients

This imbalance is understandable, as GLP-1 RAs were originally developed for diabetes and weight management, and their effects on substance use have been discovered more recently

GLP-1 is the hormone responsible for inhibiting the production of glucagon and promoting the production of insulin

There are also questions as to whether patients and the medical community were fully warned about what those health risks were

In 2026, were expanding the apps training and nutrition functionality to further integrate the digital and in-club experience, he adds

In some cases, pharma patient-support portals have API links to ePA solutions: when a patient enrolls in a manufacturer program, they can trigger an ePA message with the required financial assistance details attached